{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=11", "query": { "intervention": "dose level 1", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 29083, "total_pages": 2909, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T20:35:38.157Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01367626", "title": "Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roxane Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 28, "start_date": "2008-03", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-11-09T20:35:38.157Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01367626" }, { "nct_id": "NCT01476787", "title": "Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab-CHOP", "type": "DRUG" }, { "name": "Rituximab-CVP", "type": "DRUG" }, { "name": "Rituximab-Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1030, "start_date": "2011-12-29", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-11-09T20:35:38.157Z", "location_count": 26, "location_summary": "Chandler, Arizona • Fullerton, California • Los Angeles, California + 21 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Englewood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476787" }, { "nct_id": "NCT03326193", "title": "A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 105, "start_date": "2017-12-12", "completion_date": "2024-07-12", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-11-09T20:35:38.157Z", "location_count": 29, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Mesa, Arizona + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03326193" }, { "nct_id": "NCT04224493", "title": "A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Follicular Lymphoma", "Follicular Lymphoma", "Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" }, { "name": "Lenalidomide", "type": "COMBINATION_PRODUCT" }, { "name": "Rituximab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 599, "start_date": "2020-06-11", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-09T20:35:38.157Z", "location_count": 57, "location_summary": "Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04224493" }, { "nct_id": "NCT04685616", "title": "Brentuximab Vedotin in Early Stage Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Involved site radiotherapy", "type": "RADIATION" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Haematopoietic growth factor", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University College, London", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "16 Years to 69 Years" }, "enrollment_count": 1042, "start_date": "2022-04-14", "completion_date": "2032-09", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-11-09T20:35:38.157Z", "location_count": 3, "location_summary": "Stanford, California • Miami, Florida • New York, New York", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04685616" }, { "nct_id": "NCT06084416", "title": "A Study of Sovilnesib in Subjects With Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High Grade Serous Adenocarcinoma of Ovary", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Chromosomal Instability" ], "interventions": [ { "name": "Sovilnesib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Volastra Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-04-04", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-09T20:35:38.157Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Newport Beach, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Newport Beach", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06084416" }, { "nct_id": "NCT05515406", "title": "A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Leukemia, Lymphocytic, Chronic, B-Cell" ], "interventions": [ { "name": "ONO-7018", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ono Pharmaceutical Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-02-13", "completion_date": "2025-08-13", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-11-09T20:35:38.157Z", "location_count": 11, "location_summary": "Santa Monica, California • Kansas City, Missouri • Florham Park, New Jersey + 7 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Florham Park", "state": "New Jersey" }, { "city": "Greenville", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05515406" }, { "nct_id": "NCT00044538", "title": "Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "BAY59-8862 (Cytotoxic Taxane)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2001-12", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2009-06-22", "last_synced_at": "2026-11-09T20:35:38.157Z", "location_count": 7, "location_summary": "Tucson, Arizona • Waterbury, Connecticut • Louisville, Kentucky + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044538" }, { "nct_id": "NCT06503458", "title": "A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sickle Cell Disease", "Sickle Cell Anemia" ], "interventions": [], "intervention_types": [], "sponsor": "Sanguine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 52, "start_date": "2022-01-19", "completion_date": "2024-04-10", "has_results": false, "last_update_posted_date": "2024-07-16", "last_synced_at": "2026-11-09T20:35:38.157Z", "location_count": 1, "location_summary": "Woburn, Massachusetts", "locations": [ { "city": "Woburn", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06503458" }, { "nct_id": "NCT06232655", "title": "Cladribine Venetoclax in Monocytic AML", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2024-02-08", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-09T20:35:38.157Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06232655" } ] }